140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations.

Conclusions: Tolerability-guided dose adjustment of afatinib reduced treatment-related AEs without adversely affecting efficacy. Clinical trial identification: NCT00949650 and NCT01121393 Legal entity responsible for the study: Boehringer Ingelheim Funding: Boehringer Ingelheim Disclosure: M. Schuler: Employment/leadership at Universitat Duisburg-Essen, Universitatsklinikum Essen and Ruhrlandklinik; consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Institut fur Qualitat und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Lilly and Novartis; honoraries for CME presentations from Alexion, Boehringer Ingelheim, Celgene, GlaxoSmithKline, Lilly and Novartis; research funding to his institution from Boehringer Ingelheim, Bristol MyersSquibb and Novartis; and patents for Universitat DuisburgEssen. J. Yang: Advisory board participation for and honoraria from Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech, AstraZeneca, Astellas, Bayer, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology and Celgene. L.V. Sequist: Advisory board participation for Boehringer Ingelheim, Clovis, AstraZeneca, Novartis, Merrimack, Genentech, Ariad and Taiho. N. Yamamoto: Honoraria from Boehringer Ingelheim. C. Zhou: Advisory board participation for Boehringer Ingelheim and AstraZeneca, and corporate-sponsored research for Boehringer Ingelheim. K. O’Byrne: Consultation fees from Pfizer, Roche, AZD, Boehringer Ingelheim, BMS, MSD, Lilly Oncology and Novartis; honoraria for speaker’s bureaus from Pfizer, Roche, AZD, Lilly Oncology, Boehringer Ingelheim; owner of stock in CARP Pharmaceuticals and Bluesky Biosciences; organiser of the annual Brisbane Cancer Conference hosted by the Princess Alexandra Hospital Research Foundation which raises money from sponsors including AZD, Roche, MSD, BMS, Astellas, Boehringer Ingelheim, Celgene, Ipsen, Janssen, Lilly Oncology, Merck, Novartis, Pfizer, Takeda, Illumina and Thermofisher. V. Hirsh: Honoraria from Boehringer Ingelheim. T. Mok: Stock or other ownership from Sanomics LTD.; honoraria from AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GSK, Amgen, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Vertex Pharmaceuticals, BMS, AVEO u0026 Biodesix, Prime Oncology; advisory board participation for AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GSK, Novartis, SFJ Pharmaceutical, ACEA Biosciences, Vertex Pharmaceuticals, AVEO u0026 Biodesix, BMS, geneDecode Co., Ltd.; speakers bureau for AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, BI, MSD, Amgen, Janssen, Clovis Oncology, GSK, Novartis, BMS, Prime Oncology. R. Shah: Advisory board participation and honoraria for Boehringer Ingelheim. Y.-L. Wu: Speaker fees from Roche, AstraZeneca, Eli Lilly, Sanofi and Pfizer.